79155885 - AFFILIN

Information

• Trademark
• 79155885

• Source

• Serial Number

  79155885

• Registration Number

  4838850

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  July 29, 2014
  10 years ago

• Registration Date

  October 27, 2015
  9 years ago

• Transaction Date

  October 28, 2024
  8 months ago

• Status Date

  May 17, 2022
  3 years ago

• Published for Opposition Date

  August 11, 2015
  9 years ago

• Location Date

  May 17, 2022
  3 years ago

• Status Code

  707

• Employee Name

  HUSSAIN, TASNEEM

• Attorney Docket Number

  ISA-0045-T

  Attorney Name

  Adam D. Mandell

  Law Office Assigned Location Code

  M90

• Owners

  • Scil Proteins GmbH

Case File Statements

• GS0051: [Pharmaceutical and veterinary preparations for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; medical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; biochemical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis, except preparations containing theophylline; diagnostic and analytical preparations for medical and veterinary use; biological and chemical diagnostic reagents for medical use]
• GS0011: [Chemicals used in industry and science, in particular comprising antibody-like proteins or artificial proteins, except finishing agents for the preparation of synthetic and natural fibres; polypeptides and proteins for industrial purposes, including the manufacturing and purification of proteins, polypeptides, chemicals and other substances; diagnostic and analytic preparations for scientific or research use, not for medical or veterinary use; chemical reagents for analysis in laboratories, not for medical or veterinary use; biological tissue cultures for laboratories, not for medical or veterinary use; biological tissue cultures for laboratory analysis and diagnostics other than for medical or veterinary purposes]
• GS0421: Scientific and industrial research in particular in the biological, biochemical, diagnostic and pharmaceutical fields; biochemistry and pharmaceutical laboratory services; scientific and technological services, namely, scientific research, analysis, testing, in particular in the biological, biochemical, diagnostic and pharmaceutical fields; industrial research and analysis, namely, services in development of biological, biochemical, pharmaceutical and diagnostic products; research for the identification and further development of biological, biochemical, pharmaceutical and diagnostic products

Case File Event Statements

• 12/4/2014 - 10 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR

• 12/8/2014 - 10 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 6/24/2015 - 10 years ago

  12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 12/8/2014 - 10 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 12/8/2014 - 10 years ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 12/9/2014 - 10 years ago

  5 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 12/10/2014 - 10 years ago

  6 - REFUSAL PROCESSED BY MPU Type: RFRR

• 12/10/2014 - 10 years ago

  7 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 12/12/2014 - 10 years ago

  8 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 12/27/2014 - 10 years ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 6/10/2015 - 10 years ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 6/17/2015 - 10 years ago

  11 - ASSIGNED TO LIE Type: ALIE

• 6/24/2015 - 10 years ago

  13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 7/7/2015 - 9 years ago

  18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 7/22/2015 - 9 years ago

  20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 8/5/2015 - 9 years ago

  21 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R

• 8/5/2015 - 9 years ago

  22 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 7/6/2015 - 9 years ago

  14 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 7/6/2015 - 9 years ago

  15 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 7/6/2015 - 9 years ago

  16 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 7/6/2015 - 9 years ago

  17 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 7/8/2015 - 9 years ago

  19 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 8/11/2015 - 9 years ago

  23 - PUBLISHED FOR OPPOSITION Type: PUBO

• 8/11/2015 - 9 years ago

  24 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 10/27/2015 - 9 years ago

  26 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 1/27/2016 - 9 years ago

  27 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 10/27/2020 - 4 years ago

  31 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3

• 10/26/2021 - 3 years ago

  32 - TEAS SECTION 71 RECEIVED Type: ES71

• 8/21/2015 - 9 years ago

  25 - NOTIFICATION PROCESSED BY IB Type: GPNX

• 5/12/2016 - 9 years ago

  28 - FINAL DISPOSITION PROCESSED Type: FIMP

• 5/12/2016 - 9 years ago

  29 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 7/15/2016 - 8 years ago

  30 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 5/17/2022 - 3 years ago

  35 - NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED Type: NA71

• 5/10/2022 - 3 years ago

  33 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE

• 5/17/2022 - 3 years ago

  34 - REGISTERED - PARTIAL SEC 71 ACCEPTED Type: 71.P

• 4/30/2023 - 2 years ago

  39 - PARTIAL INVALIDATION PROCESSED BY THE IB Type: INNP

• 5/24/2024 - a year ago

  40 - INTERNATIONAL REGISTRATION RENEWED Type: RNWL

• 10/28/2024 - 8 months ago

  41 - COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED Type: REM4

• 1/17/2023 - 2 years ago

  36 - PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED Type: INPR

• 3/9/2023 - 2 years ago

  37 - INVALIDATION PROCESSED Type: INPC

• 3/9/2023 - 2 years ago

  38 - PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB Type: INPS